Cpcm LLC reduced its stake in Stryker Corporation (NYSE:SYK) by 36.4% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 1,653 shares of the medical technology company’s stock after selling 948 shares during the period. Cpcm LLC’s holdings in Stryker Corporation were worth $218,000 as of its most recent SEC filing.

A number of other hedge funds have also bought and sold shares of the company. Bollard Group LLC boosted its stake in shares of Stryker Corporation by 0.4% in the first quarter. Bollard Group LLC now owns 829 shares of the medical technology company’s stock worth $109,000 after buying an additional 3 shares during the last quarter. Assetmark Inc. boosted its stake in shares of Stryker Corporation by 0.3% in the first quarter. Assetmark Inc. now owns 1,274 shares of the medical technology company’s stock worth $168,000 after buying an additional 4 shares during the last quarter. Blue Chip Partners Inc. boosted its stake in shares of Stryker Corporation by 0.3% in the first quarter. Blue Chip Partners Inc. now owns 1,775 shares of the medical technology company’s stock worth $234,000 after buying an additional 6 shares during the last quarter. Guardian Life Insurance Co. of America boosted its stake in shares of Stryker Corporation by 0.8% in the first quarter. Guardian Life Insurance Co. of America now owns 1,199 shares of the medical technology company’s stock worth $158,000 after buying an additional 9 shares during the last quarter. Finally, Baystate Wealth Management LLC boosted its stake in shares of Stryker Corporation by 2.1% in the first quarter. Baystate Wealth Management LLC now owns 1,066 shares of the medical technology company’s stock worth $139,000 after buying an additional 22 shares during the last quarter. 73.79% of the stock is owned by institutional investors.

Shares of Stryker Corporation (NYSE:SYK) traded up 0.71% during trading on Monday, hitting $145.21. 277,930 shares of the stock were exchanged. The firm’s 50-day moving average is $143.71 and its 200 day moving average is $135.51. The company has a market cap of $54.32 billion, a P/E ratio of 32.41 and a beta of 0.80. Stryker Corporation has a 1-year low of $106.48 and a 1-year high of $148.84.

Stryker Corporation (NYSE:SYK) last posted its quarterly earnings results on Thursday, July 27th. The medical technology company reported $1.53 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.51 by $0.02. Stryker Corporation had a return on equity of 24.26% and a net margin of 14.22%. The business had revenue of $3.01 billion for the quarter, compared to analyst estimates of $2.98 billion. During the same period last year, the company earned $1.39 EPS. Stryker Corporation’s revenue for the quarter was up 6.1% compared to the same quarter last year. Equities analysts forecast that Stryker Corporation will post $6.50 earnings per share for the current fiscal year.

The business also recently declared a quarterly dividend, which will be paid on Tuesday, October 31st. Investors of record on Friday, September 29th will be given a dividend of $0.425 per share. The ex-dividend date of this dividend is Thursday, September 28th. This represents a $1.70 annualized dividend and a yield of 1.18%. Stryker Corporation’s payout ratio is 37.95%.

TRADEMARK VIOLATION WARNING: This piece of content was originally reported by Watch List News and is the property of of Watch List News. If you are reading this piece of content on another website, it was copied illegally and republished in violation of United States and international copyright & trademark law. The original version of this piece of content can be read at https://www.watchlistnews.com/cpcm-llc-sells-948-shares-of-stryker-corporation-syk/1487494.html.

A number of brokerages have recently weighed in on SYK. Cowen and Company restated a “buy” rating and issued a $160.00 price objective (up from $150.00) on shares of Stryker Corporation in a research note on Sunday, July 30th. BidaskClub cut shares of Stryker Corporation from a “buy” rating to a “hold” rating in a research note on Monday, July 31st. Zacks Investment Research cut shares of Stryker Corporation from a “buy” rating to a “hold” rating in a research note on Thursday, July 27th. Oppenheimer Holdings, Inc. set a $148.00 price objective on shares of Stryker Corporation and gave the stock a “hold” rating in a research note on Friday, July 28th. Finally, Royal Bank Of Canada boosted their price objective on shares of Stryker Corporation from $140.00 to $155.00 and gave the stock an “outperform” rating in a research note on Friday, July 28th. Three research analysts have rated the stock with a sell rating, seven have issued a hold rating and twelve have issued a buy rating to the company’s stock. The company currently has an average rating of “Hold” and a consensus price target of $144.03.

In other news, insider David Floyd sold 7,381 shares of Stryker Corporation stock in a transaction that occurred on Monday, June 5th. The stock was sold at an average price of $144.70, for a total value of $1,068,030.70. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, insider Graham A. Mclean sold 1,124 shares of Stryker Corporation stock in a transaction that occurred on Tuesday, August 8th. The stock was sold at an average price of $146.26, for a total value of $164,396.24. Following the completion of the sale, the insider now owns 8,983 shares in the company, valued at $1,313,853.58. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 32,810 shares of company stock worth $4,754,958. 7.40% of the stock is owned by corporate insiders.

Stryker Corporation Company Profile

Stryker Corporation is a medical technology company. The Company offers a range of medical technologies, including orthopedic, medical and surgical, and neurotechnology and spine products. The Company’s segments include Orthopaedics; MedSurg; Neurotechnology and Spine, and Corporate and Other. The Orthopaedics segment includes reconstructive (hip and knee) and trauma implant systems and other related products.

Want to see what other hedge funds are holding SYK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Stryker Corporation (NYSE:SYK).

Institutional Ownership by Quarter for Stryker Corporation (NYSE:SYK)

Receive News & Ratings for Stryker Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.